In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Cardiff Oncology Inc’s stock clocked out at $3.41, down -2.57% from its previous closing price of $3.50. In other words, the price has decreased by -$2.57 from its previous closing price. On the day, 0.66 million shares were traded. CRDF stock price reached its highest trading level at $3.515 during the session, while it also had its lowest trading level at $3.35.
Ratios:
To gain a deeper understanding of CRDF’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.74 and its Current Ratio is at 4.74. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 226847520 and an Enterprise Value of 118385080. For the stock, the TTM Price-to-Sale (P/S) ratio is 328.74 while its Price-to-Book (P/B) ratio in mrq is 3.36. Its current Enterprise Value per Revenue stands at 172.071 whereas that against EBITDA is -2.574.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.72, which has changed by 1.1582279 over the last 52 weeks, in comparison to a change of 0.23809385 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $6.42, while it has fallen to a 52-week low of $1.44. The 50-Day Moving Average of the stock is -0.39%, while the 200-Day Moving Average is calculated to be 11.63%.
Shares Statistics:
It appears that CRDF traded 2.15M shares on average per day over the past three months and 991090 shares per day over the past ten days. A total of 66.52M shares are outstanding, with a floating share count of 62.53M. Insiders hold about 6.00% of the company’s shares, while institutions hold 27.01% stake in the company. Shares short for CRDF as of 1735603200 were 9507049 with a Short Ratio of 4.43, compared to 1732838400 on 8179403. Therefore, it implies a Short% of Shares Outstanding of 9507049 and a Short% of Float of 14.57.
